DEVICE WORKSHOP DAY ANTI AGING TRACK

SENSUS

Almirall (4)

Clinician satisfaction with tirbanibulin treatment’s ability to improve ‘how skin looks’ and ‘skin texture’ in the treated area, among patients with Actinic Keratosis treated with tirbanibulin in community practices across the U.S (PROAK study)

Todd Schlesinger, MD1; Leon Kircik, MD2; April Armstrong, MD3; Brian Berman, MD, PhD4; Neal Bhatia, MD5; James Del Rosso, DO6; Mark Lebwohl, MD2; Vishal A. Patel, MD7; Darrell Rigel, MD, MS2; Siva Narayanan, PhD8; Volker Koscielny, MD9 Ismail Kasujee PhD9

Patient satisfaction with tirbanibulin treatment’s ability to improve ‘how skin looks’ and ‘skin texture’ in the treated area, among patients with Actinic Keratosis treated with tirbanibulin in community practices across the U.S (PROAK study)

Leon Kircik, MD1; Todd Schlesinger, MD2; April Armstrong, MD3; Brian Berman, MD, PhD4; Neal Bhatia, MD5; James Del Rosso, DO6; Mark Lebwohl, MD1; Vishal A. Patel, MD7; Darrell Rigel, MD, MS1; Siva Narayanan, PhD8; Volker Koscielny, MD9 Ismail Kasujee PhD9

Changes in patient global assessment of acne severity and facial appearance among patients with moderate to severe non-nodular acne vulgaris administered sarecycline in community practices across the U.S: Analysis of PROSES study result

Hilary Baldwin,1 Leon Kircik,2 Andrew F. Alexis,3 James Del Rosso,4 Richard G. Fried,5 Emmy Graber,6 Julie C. Harper,7

Adelaide Hebert,8 Evan A Rieder,9 Linda Stein Gold,10 Siva Narayanan,11 Volker Koscielny,12 Ismail Kasujee12

Changes in clinician reported acne severity and clinician satisfaction with treatment outcomes among patients with moderate to severe non-nodular Acne Vulgaris administered sarecycline in community practices across the U.S: Analysis of PROSES study results

Hilary Baldwin,1 Leon Kircik,2 Andrew F. Alexis,3 James Del Rosso,4 Richard G. Fried,5 Emmy Graber,6 Julie C. Harper,7

Adelaide Hebert,8 Evan A Rieder,9 Linda Stein Gold,10 Siva Narayanan,11 Volker Koscielny,12 Ismail Kasujee12

Alphabet Health (3)

Safety of tralokinumab in pediatric patients aged 12–17 with moderate-to-severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial

Andreas Wollenberg, Michael Cork, Carsten Flohr, Anthony Bewley, Andrew Blauvelt, Chih-ho Hong, Shinichi Imafuku, Marie L.A. Schuttelaar, Eric L. Simpson, Weily Soong, Petra Arlert, Katja Lophaven, Azra Kurbasic, Lise Soldbro, Natacha Strange Vest, Amy Paller

Efficacy and safety of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis in three randomized, placebocontrolled phase 3 trials

Tiffany Mayo, April Armstrong, Leon Kircik, Jonathan

I. Silverberg, Andrew Blauvelt, Ben Esdaile, Shannon

Schneider, Thomas Mark, Melinda Gooderham, Andrew F. Alexis

Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis

Tiffany Mayo, April Armstrong, Leon Kircik, Jonathan

I. Silverberg, Andrew Blauvelt, Ben Esdaile, Shannon

Schneider, Thomas Mark, Melinda Gooderham, Andrew F.

Alexis

Burts Bees

Skin barrier and microbiome integrity in atopic dermatitis/rosacea/sensitive skin subjects using a natural retinol-alternative bakuchiol regimen

Hemali B. Gunt, PhD1, Stanley B Levy, MD2 and Zoe D. Draelos, MD3

Castle Biosciences Dr. Alison Fitzgerald

Integration of the 40-Gene Expression Profile (40GEP) test for Management and Treatment of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC)

Gaurav Singh1, Stanislav N. Tolkachjov2, Aaron S. Farberg3

Castle Biosciences Dr. Morgan-Linnell

Real-world data demonstrates improved risk stratification by the 31-gene expression profile test for clinical decisions after a negative sentinel lymph node biopsy for patients with cutaneous melanoma

Brian Martin PhD1, Christine N. Bailey, MPH1, Matthew S. Goldberg, MD1,2, Valentina Petkov, MD, MPH3, Robert W. Cook, PhD1, Kyle Covington, PhD1, Sarah Kurley, PhD1

Forefront Dermatology - Dr. Issa

First Use of Aryl Hydrocarbon Receptor (AHR) Agonist Tapinarof 1% Cream for the Treatment of Seborrheic Dermatitis – A Case Series

Naiem T. Issa, MD, PhD1,2

1Forefront Dermatology; 2Issa Research and Consulting, LLC

Excerpta Medica (6)

Dupilumab Efficacy In Patients With Chronic Spontaneous Urticaria by IgE Level: LIBERTY-CSU CUPID Study A

Marcus Maurer1,2, Thomas B. Casale3, Sarbjit S. Saini4, Moshe Ben-Shoshan5, Allen Radin6, Bola Akinlade6, Elizabeth Laws7, Leda P. Mannent8

Dupilumab Efficacy on Itch and Skin Lesions in Adult Patients With Prurigo Nodularis may be Observed Concurrently or Independently Over 24 Weeks: Results From two Phase 3 Trials

Shawn G. Kwatra1, Gil Yosipovitch2, Sonja Ständer3, Pedro Mendes-Bastos4, Tsen-Fang Tsai5, Saeko Nakajima6, Amy Praestgaard7, Ashish Bansal8, Renata Martinčová9, Noah A. Levit8, Simmi Wiggins10

Hematologic Laboratory Parameters in Adults and Children Aged 6 Months to 18 Years With Moderate-toSevere Atopic Dermatitis treated with Dupilumab

Amy S. Paller1, 2, Elaine C. Siegfried3, 4, Faisal A. Khokhar5, Tayler Gonzalez6

REAL-WORLD EFFECTIVENESS OF DUPILUMAB IN ATOPIC DERMATITIS: CONSISTENCY IN RATE AND MAGNITUDE OF IMPROVEMENT ACROSS OBSERVATIONAL STUDY METHODOLOGIES

Jerry Bagel1, Tien Q. Nguyen2, Eric Simpson3, Hermenio Lima4, Haixin Zhang5, Chien-Chia Chuang6, Debra Sierka6, Dimittri Delevry5, Moataz Daoud6, Andrew Korotzer5

Dupilumab Treatment of Children with Moderateto-Severe Atopic Dermatitis Increases Bone Alkaline Phosphatase, a Marker of Bone Mineralization

Alan D. Irvine1, Amy S. Paller2,3, Sara Hamon4, Julie Horowitz4, Annamaria Farrell4, Sarah Hatsell4, Ainara Rodríguez Marco5, Ashish Bansal4, Zhen Chen4, Sonya L. Cyr4

Onset of Atopic Comorbidities Relative to Atopic Dermatitis Diagnosis in a Real-World Setting Using an Israeli Claims Database

Yael A. Leshem1,2, Allan Becker3, William W. Busse4, Lisa A. Beck5, Clara Weil6, Moataz Daoud7, Robert Lubwama8

Prime Global (6)

Phase 2 study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Long-term follow-up

Alexander J Stratigos,1 Aleksandar Sekulic,2 Ketty Peris,3

Oliver Bechter,4 Sorilla Prey,5 Martin Kaatz,6 Karl D Lewis,7

Nicole Basset-Seguin,8 Anne Lynn S Chang,9 Stéphane

Dalle,10 Almudena Fernandez Orland,11 Lisa Licitra,12

Caroline Robert,13 Claas Ulrich,14 Axel Hauschild,15

Michael R Migden,16 Reinhard Dummer,17 Suk-Young

Yoo,18 Ebony Coates,18 Emmanuel Okoye,18 Ioannis

Bassukas,19 Carmen Loquai,20 Vincenzo De Giorgi,21

Zeynep Eroglu,22 Ralf Gutzmer,23 Jens Ulrich,24 Susana

Puig,25 Frank Seebach,18 Israel Lowy,18 Matthew G Fury18

Phase 2 confirmatory study of cemiplimab 350 mg intravenous every 3 weeks in patients with locally advanced or metastatic cutaneous squamous cell carcinoma: Study 1540 Group 6

Brett GM Hughes,1 Jean-Jacques Grob,2 Samantha E

Bowyer,3 Fiona Day,4 Rahul Ladwa,5 Brian Stein,6 Eva Muñoz-Couselo,7 Nicole Basset-Seguin,8 Alexander Guminski,9 Laurent Mortier,10 Axel Hauschild,11 Michael R Migden,12 Chrysalyne D Schmults,13 Suk-Young Yoo,14

Jocelyn Booth,14 Frank Seebach,14 Israel Lowy,14 Matthew G Fury,14 Danny Rischin15

Primary analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors

Karl D Lewis,1 Ketty Peris,2,3 Aleksandar Sekulic,4

Alexander J Stratigos,5 Lara Dunn,6 Zeynep Eroglu,7

Anne Lynn S Chang,8 Michael R Migden,9 Suk-Young

Yoo,10 Kosalai Mohan,10 Ebony Coates,10 Emmanuel

Okoye,10 Jean-François Baurain,11 Oliver Bechter,12 Axel Hauschild,13 Marcus O Butler,14 Leonel Hernandez-Aya,15†

Lisa Licitra,16,17 Rogerio I Neves,18‡ Emily S Ruiz,19 Frank Seebach,10 Israel Lowy,10 Priscila Goncalves,10 Matthew G Fury10